Correction of Hyperviscosity by Apheresis

ABSTRACT

Therapeutic apheresis is an extracorporeal blood purification technique designed for the removal of either plasma (plasmapheresis) or cellular blood components (cytapheresis). One of the main indications for the use of apheresis is in the treatment of the hyperviscosity syndromes that can result from either the presence of abnormal plasma components, such as antibodies, immune complexes, paraproteins, and cryoglobulins, or the excessive increase in blood cells as seen in polycythemia, leukemias, and myeloproliferative diseases. Apheresis involves withdrawal of anticoagulated blood via a vascular catheter, separation of different blood components by either centrifugation or membrane filtration, removal of the undesired component, and reinfusion of the remaining components with replacement fluid into the patient. The centrifugal method can be intermittent or continuous, the latter being faster and fully automated, and is principally used in North America. The membrane filtration technique, mainly used in Europe and Japan, involves the filtration of blood by filters of different pore sizes. These are used sequentially in a process called double or cascade filtration, enabling removal of specific plasma pathogens without need for replacement fluids. In paraproteinemias, hyperviscosity syndrome is most commonly seen with Waldenström's macroglobulinemia, followed by immunoglobulin (Ig) A and IgG₃ multiple myeloma. Single plasmapheresis with one plasma volume replacement (about 3 L) usually results in a dramatic improvement in patients with macrogobulinemia because of its predominant intravascular distribution, whereas repeated plasmapheresis is necessary with other types of paraproteins. Cryofiltration apheresis using a high-capacity cryofilter is specific for the removal of cryoglobulins. In leukemias with hyperleukocytosis, there are no evidence-based guidelines for use of leukapheresis, but it is commonly initiated when white blood cells (WBC) are > 100,000/μL or even with lower counts if leukostasis symptoms are present, especially in acute myeloid leukemia. Erythrocytapheresis and plateletpheresis are mostly used in the acute management of symptomatic patients with polycythemia vera (PV), essential thrombocytosis, and sickle cell disease.

KEYWORDS

Plasmapheresis - leukapheresis - plateletpheresis - erythrocytapheresis - hyperviscosity

REFERENCES

• 1 Madore F. Plasmapheresis: technical aspects and indications.  Crit Care Clin . 2002;  18 375-392
• 2 Reimann P M, Mason P D. Plasmapheresis: technique and complications.  Intensive Care Med . 1990;  16 3-10
• 3 Siami G A, Siami F S. Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenström's gammopathy, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.  Ther Apheresis . 1999;  3 8-19
• 4 Kaplan A A. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias.  Ther Apheresis . 2001;  5 171-175
• 5 Kaplan A A. A simple and accurate method for prescribing plasma exchange.  ASAIO Trans . 1990;  36 M597-M599
• 6 Drew M J. Plasmapheresis in dysproteinemias.  Ther Apheresis . 2002;  6 45-52
• 7 Leitman S F, Ciaverella D, McLeod B. et al .Guidelines for Therapeutic Hemapheresis.  Bethesda, MD: American Association of Blood Banks; 1994
• 8 Sutton D MC, Nair R C, Rock G. et al . Complications of plasma exchange. Canadian Apheresis Study Group.  Transfusion . 1989;  29 124-127
• 9 Mokrzycki M H, Kaplan A A. Therapeutic plasma exchange: complications and management.  Am J Kidney Dis . 1994;  23 817-827
• 10 Gertz M A, Kyle R A. Hyperviscosity syndrome.  J Intensive Care Med . 1995;  10 128-141
• 11 Kwaan H C, Bongu A. The hyperviscosity syndromes.  Semin Thromb Hemost . 1999;  25 199-208
• 12 Grima K M. Therapeutic apheresis in hematological and oncological diseases.  J Clin Apheresis . 2000;  15 28-52
• 13 Patterson W P, Caldwell C W, Doll D C. Hyperviscosity syndromes and coagulopathies.  Semin Oncol . 1990;  17 210-216
• 14 Hoffkes G H, Heemann W U, Teschendorf C, Uppenkamp M, Phillipp T. Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenström's type.  Clin Nephrol . 1995;  43 335-338
• 15 Dominguez J H, Sha E. Apheresis in cryoglobulinemia complicating hepatitis C and other renal diseases.  Ther Apheresis . 2002;  6 69-76
• 16 Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L. Cryoglobulinemia vasculitis.  Curr Opin Rheumatol . 2002;  14 29-35
• 17 Siami G A, Siami F S. Current topics on cryofiltration technologies.  Ther Apheresis . 2001;  5 283-286
• 18 Porcu P, Cripe L D, Ng E W. et al . Hyperleukocytic leukemias: a review of pathophysiology, clinical presentation and management.  Leuk Lymphoma . 2000;  39 1-18
• 19 Porcu P, Farag S, Marcucci G. et al . Leukocytoreduction for acute leukemia.  Ther Apheresis . 2002;  6 15-23
• 20 Stucki A, Rivier A S, Gikic M. et al . Endothelial cell activation by myelobasts: molecular mechanisms of leukostasis and leukemic cell dissemination.  Blood . 2001;  97 2121-2129
• 21 Aul C, Gatterman N, Germing U. et al . Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia.  Leukemia Res . 1997;  21 249-253
• 22 Soares F A, Magnani-Landell G A, de Miranda Cardoso C M. Pulmonary leukostasis without hyperleukocytosis: a clinico-pathologic study of 16 cases.  Am J Hematol . 1992;  40 28-32
• 23 Cuttner J, Holland J F, Norton L. et al . Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia.  Med Pediatr Oncol . 1983;  11 76-78
• 24 Eguiguren J M, Schell M J, Crist W M. et al . Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis.  Blood . 1992;  79 871-875
• 25 Porcu P, Danielson C F, Orazi A. et al . Therapeutic leukapheresis in hyperleukocytic leukemias: lack of correlation between degree of cytoreduction and early mortality rate.  Br J Haematol . 1997;  98 433-436
• 26 Nakagawa M, Bondy G P, Waisman D. et al . The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocytes.  Blood . 1999;  93 2730-2737
• 27 Greist A. The role of blood component removal in essential and reactive thrombocytosis.  Ther Apheresis . 2002;  6 36-44
• 28 Wasserman L R, Balcerzak S P, Berk P D. et al . Influence of therapy on causes of death due to polycythemia vera.  Trans Asso Am Physicians . 1981;  94 30-38
• 29 Valbonesi M, Bruni R. Clinical application of therapeutic erythrocytapheresis (TEA).  Trans Sci . 2000;  22 183-194
• 30 Pearson T C, Weterley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.  Lancet . 1978;  2 1219-1221
• 31 Brittenham G M. Disorders of iron metabolism: iron deficiency and overload. In: Hoffmann R, Benz EJ, Shattil SJ, et al, eds. Hematology, Basic Principles and Practice New York: Churchill Livingstone 1995: 492-523
• 32 Wayne A S, Kevy S V, Nathan D G. Transfusion management of sickle cell disease.  Blood . 1993;  81 1109-1123